Back to School: How biopharma can reboot drug development. Access exclusive analysis here

KX2-391: Phase I started

Kinex began an open-label, dose-escalation, U.S.

Read the full 60 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE